Private Capital Advisors Inc. acquired a new position in shares of MacroGenics Inc (NASDAQ:MGNX) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 17,500 shares of the biopharmaceutical company’s stock, valued at approximately $332,000.
Several other large investors have also added to or reduced their stakes in the company. Point72 Asset Management L.P. boosted its position in shares of MacroGenics by 8.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,181,317 shares of the biopharmaceutical company’s stock worth $21,831,000 after acquiring an additional 96,900 shares in the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of MacroGenics by 43.9% in the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 33,438 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 10,200 shares during the period. Granite Point Capital Management L.P. acquired a new stake in shares of MacroGenics in the 3rd quarter valued at about $756,000. Pinnacle Associates Ltd. boosted its position in shares of MacroGenics by 38.3% in the 3rd quarter. Pinnacle Associates Ltd. now owns 843,175 shares of the biopharmaceutical company’s stock valued at $15,582,000 after purchasing an additional 233,657 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of MacroGenics by 56.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 283,517 shares of the biopharmaceutical company’s stock valued at $5,239,000 after purchasing an additional 102,778 shares during the period. 86.03% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently issued reports on MGNX shares. Zacks Investment Research cut MacroGenics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Cowen reissued a “buy” rating on shares of MacroGenics in a research report on Wednesday, October 25th. ValuEngine raised MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, December 1st. Raymond James Financial reissued a “buy” rating on shares of MacroGenics in a research report on Monday, December 11th. Finally, BidaskClub cut MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $30.60.
In other news, SVP Eric Blasius Risser sold 3,000 shares of the stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $22.50, for a total transaction of $67,500.00. Following the completion of the transaction, the senior vice president now directly owns 12,100 shares of the company’s stock, valued at approximately $272,250. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Jon Marc Wigginton sold 5,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,000 shares of company stock valued at $267,500. 8.30% of the stock is owned by company insiders.
Shares of MacroGenics Inc (NASDAQ:MGNX) opened at $21.86 on Friday. MacroGenics Inc has a one year low of $14.36 and a one year high of $23.90.
MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.09) by ($0.19). The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The firm’s revenue was down 48.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.97) earnings per share. research analysts forecast that MacroGenics Inc will post -0.7 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “17,500 Shares in MacroGenics Inc (MGNX) Purchased by Private Capital Advisors Inc.” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/04/private-capital-advisors-inc-invests-332000-in-macrogenics-inc-mgnx-stock.html.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.